Wei Chuen Tan‐Koi

Cost–Effectiveness Analysis of Genotyping for <i>HLA-B*5801</i> and an Enhanced Safety Program in Gout Patients Starting Allopurinol in Singapore

Di Dong, Wei Chuen Tan‐Koi, Gim Gee Teng et al. · Pharmacogenomics · 2015 · 51 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Pharmacovigilance activities in ASEAN countries

Wimon Suwankesawong, Teerapon Dhippayom, Wei Chuen Tan‐Koi et al. · Pharmacoepidemiology and Drug Safety · 2016 · 29 citations

Pharmacy, Pharmacology, Pharmacy Practice +17

Tailoring of Recommendations to Reduce Serious Cutaneous Adverse Drug Reactions: A Pharmacogenomics Approach

Wei Chuen Tan‐Koi, Cynthia Sung, Yong Yeow Chong et al. · Pharmacogenomics · 2017 · 20 citations

Medicine, Dermatology, Pharmacology +17

Health regulatory communications of well-established safety-related pharmacogenomics associations in six developed countries: an evaluation of alignment

Wei Chuen Tan‐Koi, Evelyn S H Lim, Yik‐Ying Teo · The Pharmacogenomics Journal · 2016 · 11 citations

Pharmacy, Pharmacology, Pharmacogenetics +14

Is HLA-B*58:01 Genotyping Cost Effective in Guiding Allopurinol use in Gout Patients with Chronic Kidney Disease?

Gim Gee Teng, Wei Chuen Tan‐Koi, Di Dong et al. · Pharmacogenomics · 2020 · 10 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +15